Skip to content

Released Nov 14, 2024, after the close

10-Q filed Nov 14, 2024, 45 days after period end · 0001493152-24-045933

Q2 2025 · 10-Q
Revenue$18.88M+33.4% vs Q2 2024+0.4% vs Q1 2025
Net Income-$11.04MN/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.01N/M vs Q2 2024no prior Q1 2025 on file
Gross Profit$8,197,428+27.1%
Operating Income$3,484,943+81.0%
Operating Cash Flowderived$1,456,844N/M
Free Cash Flowderived$1,364,399—
Margins · derived
Gross margin43.4%−2.1 pt vs Q2 2024
Operating margin18.5%+4.9 pt vs Q2 2024
Net margin-58.5%−163.9 pt vs Q2 2024

What the release said

The release

Same quarter

MetricQ2 2025Q2 2024Q2 2023Q2 2022
Revenue$18.88M$14.16M$8.59M$8.56M
Net Income-$11.04M$14.93M$1.52M$1.80M
EPS Diluted-$0.01$0.01$0.00$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Elite Pharmaceuticals Inc · CIK 1053369 · Engraved from SEC EDGAR